B
Brian J. P. Huntly
Researcher at University of Cambridge
Publications - 168
Citations - 21295
Brian J. P. Huntly is an academic researcher from University of Cambridge. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 54, co-authored 144 publications receiving 19135 citations. Previous affiliations of Brian J. P. Huntly include Cambridge University Hospitals NHS Foundation Trust & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine,Ross L. Levine,Martha Wadleigh,Jan Cools,Benjamin L. Ebert,Benjamin L. Ebert,Gerlinde Wernig,Brian J. P. Huntly,Titus J. Boggon,Iwona Wlodarska,Jennifer J. Clark,Sandra A. Moore,Jennifer Adelsperger,Sumin Koo,Jeffrey C. Lee,Stacey Gabriel,Thomas Mercher,Alan D. D'Andrea,Stefan Fröhling,Konstanze Döhner,Peter Marynen,Peter Vandenberghe,Ruben A. Mesa,Ayalew Tefferi,James D. Griffin,Michael J. Eck,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Todd R. Golub,Stephanie J. Lee,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +36 more
TL;DR: High-throughput DNA resequencing identified a recurrent somatic missense mutation JAK2V617F in granulocyte DNA samples of 121 of 164 PV patients, of which 41 had homozygous and 80 had heterozygous mutations.
Journal ArticleDOI
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
Jyoti Nangalia,Charles E. Massie,E J Baxter,Francesca L. Nice,Gunes Gundem,David C. Wedge,Edward Avezov,Juan Li,Karoline Kollmann,David G. Kent,Athar Aziz,Anna L. Godfrey,Jonathon Hinton,Inigo Martincorena,P Van Loo,Amy V. Jones,Paola Guglielmelli,P. S. Tarpey,Heather P. Harding,J.D. Fitzpatrick,C.T. Goudie,Christina A. Ortmann,Stephen J. Loughran,Keiran Raine,David R. Jones,Adam Butler,Jon W. Teague,Sarah O’Meara,Stuart McLaren,M. Bianchi,Yvonne Silber,D. Dimitropoulou,David Bloxham,L. Mudie,Mark Maddison,Bruce W. S. Robinson,Clodagh Keohane,Cathy MacLean,Kate Hill,Kim Orchard,Sudhir Tauro,Ming-Qing Du,Mel Greaves,David G. Bowen,Brian J. P. Huntly,Claire N. Harrison,Nicholas C.P. Cross,David Ron,Alessandro M. Vannucchi,Elli Papaemmanuil,Peter J. Campbell,Anthony R. Green +51 more
TL;DR: Somatic mutations in the endoplasmic reticulum chaperone CALR were found in a majority of patients with myeloproliferative neoplasms with nonmutated JAK2, a finding consistent with its role as an initiating mutation in some patients.
Journal ArticleDOI
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress.
Zuzana Tothova,Zuzana Tothova,Ramya Kollipara,Brian J. P. Huntly,Benjamin H. Lee,Benjamin H. Lee,Diego H. Castrillon,Dana E. Cullen,Dana E. Cullen,Elizabeth P. McDowell,Elizabeth P. McDowell,Suzan Lazo-Kallanian,Ifor R. Williams,Christopher Sears,Scott A. Armstrong,Emmanuelle Passegué,Ronald A. DePinho,D. Gary Gilliland,D. Gary Gilliland +18 more
TL;DR: FoxO proteins play essential roles in the response to physiologic oxidative stress and thereby mediate quiescence and enhanced survival in the HSC compartment, a function that is required for its long-term regenerative potential.
Journal ArticleDOI
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
Ellen Weisberg,Paul W. Manley,Werner Breitenstein,Josef Brüggen,Sandra W. Cowan-Jacob,Arghya Ray,Brian J. P. Huntly,Doriano Fabbro,Gabriele Fendrich,Elizabeth Hall-Meyers,Andrew L. Kung,Andrew L. Kung,Jürgen Mestan,George Q. Daley,Linda Callahan,Laurie Catley,Cara Cavazza,Azam Mohammed,Donna Neuberg,Renee D. Wright,D. Gary Gilliland,James D. Griffin +21 more
TL;DR: AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models, suggests this is a promising new inhibitor for the therapy of CML and Ph+ ALL.
Journal ArticleDOI
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson,Rab K. Prinjha,Antje Dittmann,George Giotopoulos,Marcus Bantscheff,Wai-In Chan,Samuel Robson,Chun-wa Chung,Carsten Hopf,Mikhail M. Savitski,Carola Huthmacher,Emma Gudgin,Dave Lugo,Soren Beinke,Trevor D. Chapman,Emma J. Roberts,Peter Ernest Soden,Kurt R. Auger,Olivier Mirguet,Konstanze Doehner,Ruud Delwel,Alan Kenneth Burnett,Phillip Jeffrey,Gerard Drewes,Kevin Lee,Brian J. P. Huntly,Tony Kouzarides +26 more
TL;DR: It is shown that a novel small molecule inhibitor of the BET family, GSK1210151A (I-BET151), has profound efficacy against human and murine MLL-fusion leukaemic cell lines, through the induction of early cell cycle arrest and apoptosis, establishing the displacement of BET proteins from chromatin as a promising epigenetic therapy for these aggressive leukaemias.